PTC Therapeutics, Inc. (PTCT)
NASDAQ
60.59
-2.45 (-3.89%)
Closed
Oct 23, 2026
Day's Range
59.9763.49
52 wk Range
58.8090.87
Financial Statements - PTCT - PTC Therapeutics, Inc.
Revenue
1.73B▲ 114.5%
Net Income
682.64M▲ 287.9%Net Margin 39.4%
EBITDA
877.23M▲ 2380.9%
Free Cash Flow
411.18M▲ 326.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M | 380.76M |
| Cost of Goods | 47.01M | 57.39M | 65.48M | 44.67M | 32.32M | 18.94M |
| Gross Profit | 1.68B | 749.38M | 872.33M | 654.12M | 506.26M | 361.82M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 856.50M | -146.74M | -349.40M | -439.92M | -374.94M | -397.87M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -7.65M | -49.37M | -217.52M | -56.69M | -57.37M | 51.29M |
| Pre Tax Income | 696.61M | -363.11M | -696.11M | -587.48M | -518.34M | -402.93M |
| Income Tax | 13.97M | 176K | -69.50M | -28.47M | 5.56M | 35.22M |
| Net Income | 682.64M | -363.29M | -626.60M | -559.01M | -523.90M | -438.16M |
| EPS Basic | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 |
| EPS Diluted | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 |
| Basic Shares Outstanding | 79.53M | 76.84M | 74.83M | 71.72M | 70.46M | 66.02M |
| Diluted Shares Outstanding | 79.53M | 76.84M | 74.83M | 71.72M | 70.46M | 66.02M |
| Ebit | 848.84M | -196.12M | -566.93M | -496.61M | -432.31M | -346.58M |
| Ebitda | 877.23M | 35.36M | -102.68M | -360.29M | -368.68M | -269.19M |
| Net Income Continuous Operations | 682.64M | -363.29M | -626.60M | -559.01M | -523.90M | -438.16M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
